LONDON, Feb 5 (Reuters) - GlaxoSmithKline has liftedits stake in its publicly-listed Indian consumer healthcaresubsidiary to 72.5 percent from 43.2 percent,deepening its footprint in emerging markets and non-prescriptionproducts.
David Redfern, GSK's chief strategy officer, said on Tuesdaythe 568 million pounds ($894 million) Indian transaction would"further increase our exposure to a key emerging market".
Britain's biggest drugmaker announced plans to acquirelarger holdings in both its Indian and Nigerian consumer productbusinesses in November.